Filtros de búsqueda

Lista de obras de Josep Baselga

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

artículo científico publicado en 2017

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

artículo científico publicado en 2013

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

artículo científico publicado en 2007

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis

artículo científico publicado en 2007

A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancer ⬇️

artículo científico publicado el 1 de noviembre de 2001

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

artículo científico publicado en 2005

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

artículo científico publicado en 2013

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

artículo científico publicado en 2010

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

artículo científico publicado en 2004

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases

artículo científico publicado en 2014

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

artículo científico publicado en 2014

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

artículo científico publicado en 2003

AACR Cancer Progress Report 2013.

artículo científico publicado en 2013

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

artículo científico publicado en 2011

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

scientific article published on 13 January 2020

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

article

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

artículo científico publicado en 2016

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

artículo científico publicado en 2001

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

artículo científico publicado en 2017

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

artículo científico publicado en 2011

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

artículo científico publicado en 2015

Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.

artículo científico publicado en 2008

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

artículo científico publicado en 2013

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery

artículo científico publicado en 2002

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial

artículo científico publicado en 2016

BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS

BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study

artículo científico publicado en 2018

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status

artículo científico publicado en 2015

Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck

artículo científico publicado en 2009

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

artículo científico publicado en 2008

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity

artículo científico publicado en 2008

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

artículo científico publicado en 2014

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice ⬇️

artículo científico publicado el 1 de mayo de 2003

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

artículo científico publicado en 2014

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

artículo científico publicado en 2004

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

artículo científico publicado en 2006

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

article

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

artículo científico

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

artículo científico publicado en 2008

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

artículo científico publicado en 1998

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

scientific article published on 01 November 2019

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

artículo científico publicado en 2013

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

artículo científico publicado en 2013

Epidermal growth factor receptor targeting in cancer

artículo científico publicado en 2006

Epithelial growth factor receptor interacting agents

artículo científico publicado en 2002

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

artículo científico publicado en 2008

European Code Against Cancer and scientific justification: third version (2003).

artículo científico publicado en 2003

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

artículo científico publicado en 2014

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

artículo científico publicado en 2013

Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs

artículo científico publicado en 2004

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

artículo científico publicado en 2014

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity

artículo científico publicado en 1996

Focus on breast cancer

artículo científico publicado en 2002

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

artículo científico publicado en 2012

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

artículo científico publicado en 2000

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

artículo científico publicado en 2015

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion

artículo científico publicado en 2011

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

artículo científico publicado en 2013

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

artículo científico publicado en 2013

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene

artículo científico publicado en 2007

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

artículo científico

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

artículo científico publicado en 2020

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

artículo científico publicado en 2009

LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

artículo científico publicado en 2008

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

artículo científico publicado en 2009

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

artículo científico publicado en 2013

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

artículo científico publicado en 2005

Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression

artículo científico publicado en 2015

Mechanism of action of anti-HER2 monoclonal antibodies

artículo científico publicado en 2001

Mechanism of action of trastuzumab and scientific update ⬇️

artículo científico publicado el 1 de octubre de 2001

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines

artículo científico publicado en 2008

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

artículo científico publicado en 2010

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

artículo científico publicado en 2018

Novel targeted therapies in the treatment of gastric and esophageal cancer

artículo científico publicado en 2005

Oncologist use and perception of large panel next-generation tumor sequencing

artículo científico publicado en 2017

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

artículo científico publicado en 2008

PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analy

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

artículo científico publicado en 2011

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

artículo científico publicado en 2017

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

artículo científico publicado en 2013

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

artículo científico publicado en 2002

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience

artículo científico publicado en 2017

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

artículo científico publicado en 2014

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

artículo científico publicado en 2017

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial

artículo científico publicado en 2013

Pharmacodynamic endpoints in primary breast cancer

artículo científico publicado en 2007

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

artículo científico publicado en 2002

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ⬇️

artículo científico publicado el 1 de octubre de 2001

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients

artículo científico publicado en 2008

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2011

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2013

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

artículo científico publicado en 2012

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

artículo científico publicado en 1996

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

artículo científico publicado en 2014

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

artículo científico publicado en 2003

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

artículo científico publicado en 2011

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

artículo científico publicado en 2015

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

artículo científico publicado en 2009

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

artículo científico publicado en 2010

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts ⬇️

artículo científico publicado el 1 de julio de 1998

Recurrent and functional regulatory mutations in breast cancer

artículo científico publicado en 2017

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity

artículo científico publicado en 2006

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

artículo científico publicado en 2017

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

artículo científico publicado en 2008

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

artículo científico publicado en 2015

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

artículo científico publicado en 2002

Sequence analysis of mutations and translocations across breast cancer subtypes

artículo científico publicado en 2012

Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study ⬇️

artículo científico publicado el 1 de octubre de 2003

Status of PI3K inhibition and biomarker development in cancer therapeutics

scientific article published on 27 August 2009

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

artículo científico publicado en 2003

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

artículo científico publicado en 2016

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma

artículo científico publicado en 2009

Targeted therapy in advanced colon cancer: the role of new therapies

artículo científico publicado en 2004

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells ⬇️

artículo científico publicado el 5 de agosto de 2013

Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes

artículo científico publicado en 2002

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

artículo científico publicado en 2007

The AURORA initiative for metastatic breast cancer

artículo científico publicado en 2014

The epidermal growth factor receptor as a target for therapy in breast carcinoma

artículo científico publicado en 1994

The future of breast cancer research in danger

artículo científico publicado en 2002

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors

artículo científico publicado en 2016

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

artículo científico publicado en 2001

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

artículo científico publicado en 2005

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

artículo científico publicado en 2015

Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.

artículo científico publicado en 1999

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

artículo científico publicado en 2010

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

artículo científico publicado en 2014

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

artículo científico publicado en 2010

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

artículo científico

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

artículo científico

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

artículo científico publicado en 2004

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect ⬇️

artículo científico publicado el 19 de diciembre de 2001

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

artículo científico publicado en 2001

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

artículo científico publicado en 2016

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells

artículo científico publicado en 2003

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

artículo científico publicado en 2006

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda